Developer docs
API playgroundTry for free, no card

Search company profiles

Brighten Optix

Full company profile

uuid002vsv4

Namestring
Brighten Optix
Legal namestring
Brighten Optix Corp (亨泰光學)
Company typeenum
Private
Founded yearint
1969
Descriptiontext

Brighten Optix (亨泰光學) is a Taiwan-based ophthalmic goods manufacturer founded in 1976, headquartered in Taipei. The company produces hard contact lenses, corneal plastic films, and related products, with a specialty focus on myopia control lenses designed to slow myopia progression in children and adults and to enhance visual performance. Its core technology is concentrated in contact lens design and fabrication for vision correction and myopia management, rather than in software, electronics, or AI-driven products.

The company operates a B2B2C distribution model, reaching end consumers through two primary channels: medical institutions (hospitals and clinics that recommend and dispense lenses to patients) and eyewear retailers (optical stores selling lenses to consumers). Its customer base is concentrated in Taiwan, with no demonstrated international sales footprint prior to the 2024 acquisition. The website copy emphasizes collaboration with medical institutions and eyewear channels under the brand positioning of being 'a visual performance company.'

In 2024, Brighten Optix was acquired by Carl Zeiss AG for NT$5.4 billion (approximately US$165 million), making it a wholly-owned subsidiary of the German optics and photonics group. Following the acquisition, ZEISS announced plans to expand R&D teams in Hsinchu by at least 50% and to leverage Brighten Optix within its broader strategy spanning medical optics, semiconductor inspection, and advanced optical technologies. The company is privately held and currently operates with 101-250 employees, with detailed revenue not publicly disclosed.

Short descriptiontext

Brighten Optix is a Taiwan-based contact lens manufacturer founded in 1976, specializing in myopia control and visual performance lenses distributed through medical institutions and eyewear retailers, now a wholly-owned subsidiary of Carl Zeiss AG following its 2024 acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic contact lenses, myopia control lenses, vision correction products, corneal plastic films, contact lens manufacturing
Industry2 codes
PRIMARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAK
Contact Lens Specialty & Myopia Control
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmic Contact Lenses
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contact Lens Sales
TypeHardware Sales
Description

Sale of contact lenses for visual performance and myopia control applications

brightenoptix.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Brighten Optix (亨泰光學) manufactures ophthalmic goods including hard contact lenses and corneal plastic films, with a specialization in myopia control lenses and visual performance enhancement products. The company supplies its contact lens products to medical institutions (hospitals and clinics) and eyewear retailers across Taiwan, who serve as distribution and recommendation channels for vision correction and myopia control treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Taiwan myopia control lenses market growing from US$49.30 million (2024) to US$140.60 million (2033)
Product overview1 text field

Brighten Optix (亨泰光學) is a visual performance company that offers contact lenses, particularly specializing in myopia control lenses. The company operates as a single-product focused business, providing visual performance solutions through contact lenses to medical institutions and eyewear retailers. The company was acquired by Carl Zeiss AG in 2024 for NT$5.4 billion, expanding Zeiss's advanced optics portfolio in the semiconductor and optical technology sectors.

Product and service3 records
1Myopia Control Contact Lenses
CategoryMyopia Control Lenses
Description

Specialized contact lenses designed for myopia control and visual performance enhancement, addressing myopia progression particularly in children. Sold through medical institutions and eyewear retailers in Taiwan.

2Hard Contact Lenses
CategoryOphthalmic Contact Lenses
Description

Hard (rigid gas permeable) contact lenses for vision correction, serving patients with refractive errors through hospitals, clinics, and optical retail channels in Taiwan.

3Corneal Plastic Films
CategoryOphthalmic Films
Description

Ophthalmic corneal plastic films manufactured by Brighten Optix as part of its ophthalmic goods product line. Used in clinical vision correction applications and supplied through medical channels.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Carl Zeiss AG acquired Brighten Optix Corp for NT$5.4 billion as part of its strategic expansion into advanced chip manufacturing, packaging inspections, and optical technology. ZEISS plans to expand R&D teams by at least 50% in Hsinchu as part of its long-term investment plan. The acquisition provides Brighten Optix with access to Zeiss's global resources and advanced optics capabilities.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bausch + Lomb is a major global contact lens and ophthalmic goods manufacturer with brands including Biotrue and Ultra. Comparable to Brighten Optix in manufacturing contact lenses and serving vision correction consumers through medical and retail channels.

TypeBroad incumbent
Description

CooperVision is one of the world's leading soft contact lens manufacturers with a strong myopia management portfolio (MiSight). Directly comparable to Brighten Optix in myopia control contact lenses and B2B2C distribution through eye care professionals.

TypeDirect peer
Description

Menicon is a Japan-based specialty contact lens manufacturer with deep expertise in orthokeratology and myopia control lenses. Closely comparable to Brighten Optix as a regional specialist in hard/RGP contact lenses and myopia management, serving similar medical institution and optical retail channels in Asia.

TypeBroad incumbent
Description

Johnson & Johnson Vision, through its Acuvue brand, is one of the world's largest contact lens manufacturers with a broad portfolio including myopia management lenses. Directly comparable to Brighten Optix in core contact lens technology and vision correction end markets, though at vastly larger scale and global reach.

TypeBroad incumbent
Description

Alcon is a global leader in eye care with a major contact lens and surgical/ophthalmic franchise. Highly comparable to Brighten Optix as a contact lens and vision care specialist operating at global scale, with overlapping myopia management and specialty lens offerings.

TypeDirect peer
Description

HOYA Corporation operates a significant ophthalmic lens and contact lens business across Asia and globally. Comparable to Brighten Optix in ophthalmic lens manufacturing and as a Japan/Asia-based vision care company with overlapping product categories and distribution models.

TypeEmerging player
Description

Euclid Systems is a specialty contact lens company focused on orthokeratology and myopia management lenses. Comparable to Brighten Optix as a niche player in myopia control lens technology targeting the same clinical and pediatric patient segments.

TypeDirect peer
Description

Paragon Vision Sciences is a specialty contact lens manufacturer known for orthokeratology and corneal reshaping lenses used in myopia control. Directly comparable to Brighten Optix in specialty/hard contact lens technology and myopia management end markets.

9Carl Zeiss Meditec
TypeOthers
Description

Carl Zeiss Meditec is the medical technology arm of Carl Zeiss AG, Brighten Optix's parent company, focused on ophthalmic diagnostic and surgical equipment. Adjacent parent-company ecosystem player that shares ophthalmic end markets and now provides distribution, R&D, and capital backing to Brighten Optix.

10Visioneering Technologies
TypeEmerging player
Description

Visioneering Technologies is a US-based specialty contact lens company focused on myopia management and presbyopia solutions. Comparable to Brighten Optix as a smaller-scale specialist in vision performance and myopia control lenses sold through eye care professionals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brighten Optix

Ophthalmic Contact Lensesbrightenoptix.com.tw

Brighten Optix is a Taiwan-based contact lens manufacturer founded in 1976, specializing in myopia control and visual performance lenses distributed through medical institutions and eyewear retailers, now a wholly-owned subsidiary of Carl Zeiss AG following its 2024 acquisition.

What Brighten Optix does

Brighten Optix (亨泰光學) is a Taiwan-based ophthalmic goods manufacturer founded in 1976, headquartered in Taipei. The company produces hard contact lenses, corneal plastic films, and related products, with a specialty focus on myopia control lenses designed to slow myopia progression in children and adults and to enhance visual performance. Its core technology is concentrated in contact lens design and fabrication for vision correction and myopia management, rather than in software, electronics, or AI-driven products.

The company operates a B2B2C distribution model, reaching end consumers through two primary channels: medical institutions (hospitals and clinics that recommend and dispense lenses to patients) and eyewear retailers (optical stores selling lenses to consumers). Its customer base is concentrated in Taiwan, with no demonstrated international sales footprint prior to the 2024 acquisition. The website copy emphasizes collaboration with medical institutions and eyewear channels under the brand positioning of being 'a visual performance company.'

In 2024, Brighten Optix was acquired by Carl Zeiss AG for NT$5.4 billion (approximately US$165 million), making it a wholly-owned subsidiary of the German optics and photonics group. Following the acquisition, ZEISS announced plans to expand R&D teams in Hsinchu by at least 50% and to leverage Brighten Optix within its broader strategy spanning medical optics, semiconductor inspection, and advanced optical technologies. The company is privately held and currently operates with 101-250 employees, with detailed revenue not publicly disclosed.

Brighten Optix firmographics

Firmographics
Name
Brighten Optix
Legal name
Brighten Optix Corp (亨泰光學)
Website
https://brightenoptix.com.tw
Company type
Private
Founded year
1969
Operating status
Acquired
Headcount range
51–100 employees
Short description
Brighten Optix is a Taiwan-based contact lens manufacturer founded in 1976, specializing in myopia control and visual performance lenses distributed through medical institutions and eyewear retailers, now a wholly-owned subsidiary of Carl Zeiss AG following its 2024 acquisition.
Ownership category
akta.pro rank

Brighten Optix industry classification

Industry
Product category
Ophthalmic Contact Lenses
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAK
Contact Lens Specialty & Myopia Control

Keywords

  • Ophthalmic contact lenses
  • Myopia control lenses
  • Vision correction products
  • Corneal plastic films
  • Contact lens manufacturing

Where Brighten Optix is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices1 record

Markets served

Brighten Optix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contact Lens Sales: Sale of contact lenses for visual performance and myopia control applications

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Brighten Optix product offering

Product offering

Core offering

Brighten Optix (亨泰光學) manufactures ophthalmic goods including hard contact lenses and corneal plastic films, with a specialization in myopia control lenses and visual performance enhancement products. The company supplies its contact lens products to medical institutions (hospitals and clinics) and eyewear retailers across Taiwan, who serve as distribution and recommendation channels for vision correction and myopia control treatments.

Product overview

Brighten Optix (亨泰光學) is a visual performance company that offers contact lenses, particularly specializing in myopia control lenses. The company operates as a single-product focused business, providing visual performance solutions through contact lenses to medical institutions and eyewear retailers. The company was acquired by Carl Zeiss AG in 2024 for NT$5.4 billion, expanding Zeiss's advanced optics portfolio in the semiconductor and optical technology sectors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Myopia Control Contact Lenses Specialized contact lenses designed for myopia control and visual performance enhancement, addressing myopia progression particularly in children. Sold through medical institutions and eyewear retailers in Taiwan.
  • Hard Contact Lenses Hard (rigid gas permeable) contact lenses for vision correction, serving patients with refractive errors through hospitals, clinics, and optical retail channels in Taiwan.
  • Corneal Plastic Films Ophthalmic corneal plastic films manufactured by Brighten Optix as part of its ophthalmic goods product line. Used in clinical vision correction applications and supplied through medical channels.

Quantifiable outcome

  • Taiwan myopia control lenses market growing from US$49.30 million (2024) to US$140.60 million (2033)

Companies that use Brighten Optix

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Brighten Optix technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Brighten Optix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Carl Zeiss AGflagshipStrategic or Co-development Partner · 24 March 2026Carl Zeiss AG acquired Brighten Optix Corp for NT$5.4 billion as part of its strategic expansion into advanced chip manufacturing, packaging inspections, and optical technology. ZEISS plans to expand R&D teams by at least 50% in Hsinchu as part of its long-term investment plan. The acquisition provides Brighten Optix with access to Zeiss's global resources and advanced optics capabilities.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Brighten Optix competitors and assessment

Company assessment

Broad incumbents

  • Bausch + Lomb: Bausch + Lomb is a major global contact lens and ophthalmic goods manufacturer with brands including Biotrue and Ultra. Comparable to Brighten Optix in manufacturing contact lenses and serving vision correction consumers through medical and retail channels.
  • CooperVision: CooperVision is one of the world's leading soft contact lens manufacturers with a strong myopia management portfolio (MiSight). Directly comparable to Brighten Optix in myopia control contact lenses and B2B2C distribution through eye care professionals.
  • Johnson & Johnson Vision: Johnson & Johnson Vision, through its Acuvue brand, is one of the world's largest contact lens manufacturers with a broad portfolio including myopia management lenses. Directly comparable to Brighten Optix in core contact lens technology and vision correction end markets, though at vastly larger scale and global reach.
  • Alcon: Alcon is a global leader in eye care with a major contact lens and surgical/ophthalmic franchise. Highly comparable to Brighten Optix as a contact lens and vision care specialist operating at global scale, with overlapping myopia management and specialty lens offerings.

Direct peers

  • Menicon: Menicon is a Japan-based specialty contact lens manufacturer with deep expertise in orthokeratology and myopia control lenses. Closely comparable to Brighten Optix as a regional specialist in hard/RGP contact lenses and myopia management, serving similar medical institution and optical retail channels in Asia.
  • HOYA Corporation: HOYA Corporation operates a significant ophthalmic lens and contact lens business across Asia and globally. Comparable to Brighten Optix in ophthalmic lens manufacturing and as a Japan/Asia-based vision care company with overlapping product categories and distribution models.
  • Paragon Vision Sciences: Paragon Vision Sciences is a specialty contact lens manufacturer known for orthokeratology and corneal reshaping lenses used in myopia control. Directly comparable to Brighten Optix in specialty/hard contact lens technology and myopia management end markets.

Emerging players

  • Euclid Systems Corporation: Euclid Systems is a specialty contact lens company focused on orthokeratology and myopia management lenses. Comparable to Brighten Optix as a niche player in myopia control lens technology targeting the same clinical and pediatric patient segments.
  • Visioneering Technologies: Visioneering Technologies is a US-based specialty contact lens company focused on myopia management and presbyopia solutions. Comparable to Brighten Optix as a smaller-scale specialist in vision performance and myopia control lenses sold through eye care professionals.

Others

  • Carl Zeiss Meditec: Carl Zeiss Meditec is the medical technology arm of Carl Zeiss AG, Brighten Optix's parent company, focused on ophthalmic diagnostic and surgical equipment. Adjacent parent-company ecosystem player that shares ophthalmic end markets and now provides distribution, R&D, and capital backing to Brighten Optix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Brighten Optix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brighten Optix leadership team

Management profile

Number of profiles

Brighten Optix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brighten Optix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brighten Optix

What does Brighten Optix do?

Brighten Optix (亨泰光學) manufactures ophthalmic goods including hard contact lenses and corneal plastic films, with a specialization in myopia control lenses and visual performance enhancement products. The company supplies its contact lens products to medical institutions (hospitals and clinics) and eyewear retailers across Taiwan, who serve as distribution and recommendation channels for vision correction and myopia control treatments.

Is Brighten Optix a public or private company?

Brighten Optix is a private company. It is classified as corporate owned and is currently acquired.

When was Brighten Optix founded?

Brighten Optix was founded in 1969. It employs 51 to 100 people.

Where is Brighten Optix based?

Brighten Optix is headquartered in Taipei, Taiwan, in the Asia region.

How does Brighten Optix make money?

One revenue line is on record: contact Lens Sales.

Who are Brighten Optix's main competitors?

Broad incumbents on record are Bausch + Lomb, CooperVision, Johnson & Johnson Vision and Alcon. Direct peers are Menicon, HOYA Corporation and Paragon Vision Sciences. Emerging players are Euclid Systems Corporation and Visioneering Technologies. Carl Zeiss Meditec is listed as an others.

Does Brighten Optix have an API?

No public API is recorded for Brighten Optix.

What industry is Brighten Optix in?

Brighten Optix's product category is Ophthalmic Contact Lenses. Its primary akta.pro industry code is HLAHAJAE, Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions), with a secondary code of HLAKAKAK, Contact Lens Specialty & Myopia Control. Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Taipei TimesZeiss planning to raise investment, staff in TaiwanCarl Zeiss AG plans to increase investment and workforce in Taiwan, focusing on advanced chip manufacturing and packaging inspections to meet demand driven by artificial intelligence and high-performance computing. The company acquired Brighten Optix Corp for NT$5.4 billion and is exploring M&A opportunities in the semiconductor sector. It aims to expand R&D teams by at least 50% in Hsinchu as part of its long-term investment plan.GlobeNewswireTaiwan Myopia Control Lenses Market to Worth Over US$ 140.60 Million By 2033 | Astute AnalyticaThe Taiwan myopia control lenses market is projected to grow from US$49.30 million in 2024 to US$140.60 million by 2033, driven by aggressive government fiscal support including a Phase 2 Child Health Budget of NT$13.5 billion for 2025-2028. Brighten Optix reported record 2024 consolidated revenue of NT$766.92 million with EPS of NT$5.51 and a dividend yield of 6.29%, while Universal Vision Biotechnology achieved trailing 12-month revenue of US$134 million by September 2025. Regulatory pressure from the impending 2026 Optometry Act enforcement is forcing 4,185 retailers to seek certification, transforming the market from fragmented retail to a regulated medical device sector.ZEISSCarl Zeiss Vision International GmbH announces agreement to acquire Brighten OptixCarl Zeiss Vision International GmbH has entered a definitive agreement to acquire 100% of the shares in Brighten Optix, a leading manufacturer of orthokeratology and specialty contact lenses. This acquisition aims to enhance Zeiss's myopia management portfolio by integrating Brighten Optix's innovative products, which are currently used across Greater China and Southeast Asia. The transaction is expected to close in early 2026, pending regulatory approvals.